Processa's Vidya acquisition adds BTK inhibitor VT7208 plus a $200M private placement

Processa Pharmaceuticals, Inc.

On July 28, 2026 Processa acquired Vidya Therapeutics; VT7208, an oral CNS-penetrant BTK inhibitor, is now the lead asset in food allergy, chronic spontaneous urticaria and MS.
Received $200M gross proceeds from private placement of non-voting convertible preferred stock; investors include Bain Capital Life Sciences, Janus Henderson, RA Capital and Cormorant.
Phase 1 data: 5 mg single dose achieved >95% BTK target occupancy at 4 hours and >99% peak, sustained ~48 hours; 10 mg MAD dose hit 100% occupancy.
Phase 1 trial in 24 healthy volunteers (5-60 mg) showed no dose-limiting toxicities, no serious adverse events, no treatment-related discontinuations and no liver-safety signal; DILI-risk score 2.1.
Founder Sheila Gujrathi, M.D., who led ocrelizumab (Ocrevus) development at Roche, heads the team; company also continues legacy assets PCS499, PCS12852 and PCS11T.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.